NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
Clinical Trials
3 trialsNCT05622058 2023-02-27
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT00002866 2020-04-01
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 1 Completed